Cetuximab attenuates its cytotoxic and radiosensitizing potential by inducing fibronectin biosynthesis

Cancer Research

Volumn 73, Issue 19, 2013, Pages 5869-5879

  Eke, Iris ^a   Storch, Katja ^a   Krause, Mechthild ^a,b   Cordes, Nils ^a,b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; CETUXIMAB; FIBRONECTIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL ADHESION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG RESISTANCE; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RADIOSENSITIVITY; RADIOSENSITIZATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; WHOLE BODY RADIATION; X RAY;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL ADHESION; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; FIBRONECTINS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 8; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RADIATION-SENSITIZING AGENTS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; X-RAYS;

EID: 84885086130     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-0344     Document Type: Article

References (48)

1. Mellinghoff IK, Sawyers CL. The emergence of resistance to targeted cancer therapeutics. Pharmacogenomics 2002;3:603-23.
2. Voltz E, Gronemeyer H. A new era of cancer therapy: cancer cell targeted therapies are coming of age. Int J Biochem Cell Biol 2008;40:1-8.
3. Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 2009;21:177-84.
4. Patel R, Leung HY. Targeting the EGFR-family for therapy: biological challenges and clinical perspective. Curr Pharm Des 2012;18:2672-9.
5. Morgensztern D, Govindan R. Is there a role for cetuximab in non small cell lung cancer? Clin Cancer Res 2007;13:s4602-5.
6. Zips D, Krause M, Yaromina A, Dorfler A, Eicheler W, Schutze C, et al. Epidermal growth factor receptor inhibitors for radiotherapy: biological rationale and preclinical results. J Pharm Pharmacol 2008;60:1019-28.
7. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78.
8. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21-8.
9. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-8.
10. Ettinger DS. Emerging profile of cetuximab in non-small cell lung cancer. Lung Cancer 2009;68:332-7.
11. Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 2008;26:3351-7.
12. Guha U, Chaerkady R, Marimuthu A, Patterson AS, Kashyap MK, Harsha HC, et al. Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS. Proc Natl Acad Sci U S A 2008;105:14112-7.
13. Mack PC, Holland WS, Redman M, Lara PN Jr, Snyder LJ, Hirsch FR, et al. KRAS mutation analysis in cetuximab-treated advanced stage non-small cell lung cancer (NSCLC): SWOG experience with S0342 and S0536. J Clin Oncol (Meeting Abstracts) 2009;27:8022.
14. Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A 2012;109:E2127-33.
15. Ricono JM, Huang M, Barnes LA, Lau SK, Weis SM, Schlaepfer DD, et al. Specific cross-talk between epidermal growth factor receptor and integrin alphavbeta5 promotes carcinoma cell invasion and metastasis. Cancer Res 2009;69:1383-91.
16. Cabodi S, Morello V, Masi A, Cicchi R, Broggio C, Distefano P, et al. Convergence of integrins and EGF receptor signaling via PI3K/Akt/FoxO pathway in early gene Egr-1 expression. J Cell Physiol 2009;218:294-303.
17. Eke I, Schneider L, Forster C, Zips D, Kunz-Schughart LA, Cordes N. EGFR/JIP-4/JNK2 signaling attenuates cetuximab-mediated radiosensitization of squamous cell carcinoma cells. Cancer Res 2012;73:297-306.
18. Eke I, Sandfort V, Mischkus A, Baumann M, Cordes N. Antiproliferative effects of EGFR tyrosine kinase inhibition and radiation-induced genotoxic injury are attenuated by adhesion to fibronectin. Radiother Oncol 2006;80:178-84.
19. Eke I, Sandfort V, Storch K, Baumann M, Roper B, Cordes N. Pharmacological inhibition of EGFR tyrosine kinase affects ILKmediated cellular radiosensitization in vitro. Int J Radiat Biol 2007;83:793-802.
20. Giannelli G, Azzariti A, Fransvea E, Porcelli L, Antonaci S, Paradiso A. Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells. Br J Cancer 2004;91:1964-9.
21. Yarwood SJ, Woodgett JR. Extracellular matrix composition determines the transcriptional response to epidermal growth factor receptor activation. Proc Natl Acad Sci U S A 2001;98:4472-7.
22. Leiss M, Beckmann K, Giros A, Costell M, Fassler R. The role of integrin binding sites in fibronectin matrix assembly in vivo. Curr Opin Cell Biol 2008;20:502-7.
23. Wernert N. The multiple roles of tumour stroma. Virchows Arch 1997;430:433-43.
24. Labat-Robert J. Fibronectin in malignancy. Semin Cancer Biol 2002;12:187-95.
25. Bissell MJ, Kenny PA, Radisky DC. Microenvironmental regulators of tissue structure and function also regulate tumor induction and progression: the role of extracellular matrix and its degrading enzymes. Cold Spring Harb Symp Quant Biol 2005;70:343-56.
26. Kaspar M, Zardi L, Neri D. Fibronectin as target for tumor therapy. Int J Cancer 2006;118:1331-9.
27. Jerhammar F, Ceder R, Garvin S, Grenman R, Grafstrom RC, Roberg K. Fibronectin 1 is a potential biomarker for radioresistance in head and neck squamous cell carcinoma. Cancer Biol Ther 2010;10:1244-51.
28. Alonso CR, Pesce CG, Kornblihtt AR. The CCAAT-binding proteins CP1 and NF-I cooperate with ATF-2 in the transcription of the fibronectin gene. J Biol Chem 1996;271:22271-9.
29. Zayzafoon M, Botolin S, McCabe LR. P38 and activating transcription factor-2 involvement in osteoblast osmotic response to elevated extracellular glucose. J Biol Chem 2002;277:37212-8.
30. Liu C, Yao J, Mercola D, Adamson E. The transcription factor EGR-1 directly transactivates the fibronectin gene and enhances attachment of human glioblastoma cell line U251. J Biol Chem 2000;275:20315-23.
31. Tsuda M, Takahashi S, Takahashi Y, Asahara H. Transcriptional coactivators CREB-binding protein and p300 regulate chondrocytespecific gene expression via association with Sox9. J Biol Chem 2003;278:27224-9.
32. Eke I, Deuse Y, Hehlgans S, Gurtner K, Krause M, Baumann M, et al. beta (1) Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy. J Clin Invest 2012;122:1529-40.
33. Eke I, Koch U, Hehlgans S, Sandfort V, Stanchi F, Zips D, et al. PINCH1 regulates Akt1 activation and enhances radioresistance by inhibiting PP1alpha. J Clin Invest 2010;120:2516-27.
34. Gurtner K, Deuse Y, Butof R, Schaal K, Eicheler W, Oertel R, et al. Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression. Radiother Oncol 2011;99:323-30.
35. Eke I, Leonhardt F, Storch K, Hehlgans S, Cordes N. The small molecule inhibitor QLT0267 radiosensitizes squamous cell carcinoma cells of the head and neck. PLoS One 2009;4:e6434.
36. Lu P, Takai K, Weaver VM, Werb Z. Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb Perspect Biol 2011;3; pii-a005058.
37. Pietruszewska W, Kobos J, Bojanowska-Pozniak K, Durko M, Gryczynski M. Immunohistochemical analysis of the fibronectin expression and its prognostic value in patients with laryngeal cancer. Otolaryngol Pol 2006;60:697-702.
38. Ioachim E, Charchanti A, Briasoulis E, Karavasilis V, Tsanou H, Arvanitis DL, et al. Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur J Cancer 2002;38:2362-70.
39. Ioachim E, Michael M, Stavropoulos NE, Kitsiou E, Salmas M, Malamou-Mitsi V. A clinicopathological study of the expression of extracellular matrix components in urothelial carcinoma. BJU Int 2005;95:655-9.
40. Rintoul RC, Sethi T. The role of extracellular matrix in small-cell lung cancer. Lancet Oncol 2001;2:437-42.
41. Stevenson AF, Lange CS. Extracellular matrix (ECM) and cytoskeletal modulation of cellular radiosensitivity. Acta Oncol 1997;36:599-606.
42. Cordes N, Meineke V. Cell adhesion-mediated radioresistance (CAMRR). Extracellular matrix-dependent improvement of cell survival in human tumor and normal cells in vitro. Strahlenther Onkol 2003;179:337-44.
43. Aoudjit F, Vuori K. Integrin signaling in cancer cell survival and chemoresistance. Chemother Res Pract 2012;2012:283181.
44. Reginato MJ, Mills KR, Paulus JK, Lynch DK, Sgroi DC, Debnath J, et al. Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nat Cell Biol 2003;5:733-40.
45. Bill HM, Knudsen B, Moores SL, Muthuswamy SK, Rao VR, Brugge JS, et al. Epidermal growth factor receptor-dependent regulation of integrinmediated signaling and cell cycle entry in epithelial cells. Mol Cell Biol 2004;24:8586-99.
46. Barkovich KJ, Hariono S, Garske AL, Zhang J, Blair JA, Fan QW, et al. Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers. Cancer Discov 2012;2:450-7.
47. Nam JM, Onodera Y, Bissell MJ, Park CC. Breast cancer cells in three-dimensional culture display an enhanced radioresponse after coordinate targeting of integrin alpha5beta1 and fibronectin. Cancer Res 2010;70:5238-48.
48. Bhoumik A, Fichtman B, Derossi C, Breitwieser W, Kluger HM, Davis S, et al. Suppressor role of activating transcription factor 2 (ATF2) in skin cancer. Proc Natl Acad Sci U S A 2008;105:1674-9. Forschung